Aug. 9 at 7:38 PM
$SRTS and do you still think it’s good practice for a public company management team (father and son or any other combination) to not disclose such a huge risk?
This could trigger shareholder litigation, and should trigger a concern on what else is held back.
My three guesses are:
- The FDA penetration is not going replace the missing revenue
- no other international market growth will do that
- trans dermal could be a great technology but it will take years to become $$ meaningful
Will the
$22MILLION in cash (
$7 of which came from AR collections QoQ) by enough to get this boat to renewed growth? Will the SkinCure relationship (and HIG involvement) be a plus or a minus?
Most important, is this a family company or a public one?
Just a reminder - under similar conditions, the share price was
$2.40 two years ago.
